Regulatory Approval Clears Path for Oncolytics Biotech庐 to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data
Oncolytics Biotech (NASDAQ: ONCY) has received approval from Germany's Paul-Ehrlich-Institute to continue enrollment in Cohort 5 of the GOBLET study, which evaluates pelareorep combined with mFOLFIRINOX, with or without atezolizumab, for newly diagnosed pancreatic ductal adenocarcinoma patients.
The approval follows a positive safety review by the independent Data Safety Monitoring Board and allows for full enrollment of 30 patients in Stage 1. Early safety data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium, with initial efficacy results expected in H2 2025.
The company reports encouraging tumor response rates from an earlier GOBLET cohort, suggesting pelareorep's potential to improve outcomes for metastatic pancreatic cancer patients. The current cohort explores a different chemotherapy combination to potentially benefit a broader patient population.
Oncolytics Biotech (NASDAQ: ONCY) ha ricevuto l'approvazione dall'Istituto Paul-Ehrlich della Germania per continuare l'arruolamento nel Coorte 5 dello studio GOBLET, che valuta pelareorep combinato con mFOLFIRINOX, con o senza atezolizumab, per pazienti con adenocarcinoma duttale pancreatico appena diagnosticato.
L'approvazione segue una revisione positiva della sicurezza da parte del Data Safety Monitoring Board indipendente e consente l'arruolamento completo di 30 pazienti nella Fase 1. I dati preliminari di sicurezza saranno presentati al Simposio ASCO sui Tumori Gastrointestinali del 2025, con i risultati iniziali di efficacia previsti nella seconda met脿 del 2025.
La societ脿 riporta tassi di risposta tumorale incoraggianti da una precedente coorte GOBLET, suggerendo il potenziale di pelareorep per migliorare i risultati per i pazienti con cancro pancreatico metastatico. La coorte attuale esplora una diversa combinazione di chemioterapia per potenzialmente avvantaggiare una popolazione di pazienti pi霉 ampia.
Oncolytics Biotech (NASDAQ: ONCY) ha recibido la aprobaci贸n del Instituto Paul-Ehrlich de Alemania para continuar con la inscripci贸n en el Cohorte 5 del estudio GOBLET, que eval煤a pelareorep combinado con mFOLFIRINOX, con o sin atezolizumab, para pacientes reci茅n diagnosticados con adenocarcinoma ductal pancre谩tico.
La aprobaci贸n sigue a una revisi贸n positiva de seguridad por parte de la Junta de Monitoreo de Seguridad de Datos independiente y permite la inscripci贸n completa de 30 pacientes en la Etapa 1. Los datos iniciales de seguridad se presentar谩n en el Simposio de C谩nceres Gastrointestinales ASCO 2025, con resultados iniciales de eficacia esperados para la segunda mitad de 2025.
La empresa informa tasas de respuesta tumoral alentadoras de una cohorte anterior de GOBLET, sugiriendo el potencial de pelareorep para mejorar los resultados para los pacientes con c谩ncer de p谩ncreas metast谩sico. La cohorte actual explora una combinaci贸n diferente de quimioterapia para potencialmente beneficiar a una poblaci贸n de pacientes m谩s amplia.
鞓綌毽嫳鞀� 氚旍澊鞓ろ厤 (NASDAQ: ONCY)電� 霃呾澕 韺岇毟 鞐愲ゼ毽瀳 鞐瓣惮靻岆攵�韯� 韼犽澕霠堨槫霠�鞚� mFOLFIRINOX鞕� 頃粯 霕愲姅 霃呺鞝侅溂搿� 鞎勴厡臁鸽Μ欤茧瓿� 臁绊暕頃橃棳 靸堧 歆勲嫧霅� 旆岇灔 甏� duct 靹犾晹 頇橃瀽毳� 鞙勴暅 GOBLET 鞐瓣惮鞚� 5彀� 旖旐樃韸胳棎 雽�頃� 霌彪鞚� 瓿勳啀 項堦皜氚涭晿鞀惦媹雼�.
鞚措矆 鞀轨澑鞚� 霃呺鞝侅澑 雿办澊韯� 鞎堨爠靹� 氇媹韯半 鞙勳洂須岇潣 旮嶌爼鞝侅澑 鞎堨爠靹� 瓴�韱犾棎 霐半ジ 瓴冹澊氅�, 1雼硠鞐愳劀 30氇呾潣 頇橃瀽毳� 鞕勳爠頌� 霌彪頃� 靾� 鞛堧弰搿� 項堨毄頃╇媹雼�. 齑堦赴 鞎堨爠靹� 雿办澊韯半姅 2025雲� ASCO 鞙勳灔甏�鞎� 鞁彫歆�鞐勳棎靹� 氚滍憸霅� 鞓堨爼鞚措┌, 齑堦赴 須姤 瓴瓣臣電� 2025雲� 頃橂皹旮办棎 鞓堨儊霅╇媹雼�.
須岇偓電� 鞚挫爠 GOBLET 旖旐樃韸胳棎靹� 瓿犽鞝侅澑 膦呾枒 氚橃潙毳犾潉 氤搓碃頃橁碃 鞛堨溂氅�, 鞚措姅 韼犽澕霠堨槫霠欖澊 鞝勳澊靹� 旆岇灔鞎� 頇橃瀽鞚� 瓴瓣臣毳� 臧滌劆頃� 臧�電レ劚鞚� 鞛堨潓鞚� 鞝滌晥頃╇媹雼�. 順勳灛 旖旐樃韸鸽姅 雿� 雱撿潃 頇橃瀽 歆戨嫧鞐� 順滍儩鞚� 欷� 靾� 鞛堧姅 雼るジ 頇旐暀鞖旊矔 臁绊暕鞚� 韮愳儔頃╇媹雼�.
Oncolytics Biotech (NASDAQ: ONCY) a re莽u l'approbation de l'Institut Paul-Ehrlich d'Allemagne pour poursuivre l'enr么lement dans la Cohorte 5 de l'茅tude GOBLET, qui 茅value pelareorep combin茅 avec mFOLFIRINOX, avec ou sans atezolizumab, pour des patients nouvellement diagnostiqu茅s avec un ad茅nocarcinome canalaire pancr茅atique.
L'approbation fait suite 脿 une 茅valuation positive de s茅curit茅 par le Conseil de surveillance de la s茅curit茅 des donn茅es ind茅pendant et permet l'enr么lement complet de 30 patients 脿 l'脡tape 1. Les donn茅es pr茅liminaires de s茅curit茅 seront pr茅sent茅es au Symposium ASCO sur les cancers gastro-intestinaux 2025, avec les premiers r茅sultats d'efficacit茅 attendus au second semestre 2025.
La soci茅t茅 rapporte des taux de r茅ponse tumorale encourageants d'une cohorte GOBLET ant茅rieure, sugg茅rant le potentiel de pelareorep d'am茅liorer les r茅sultats pour les patients atteints de cancer du pancr茅as m茅tastatique. La cohorte actuelle explore une combinaison de chimioth茅rapie diff茅rente pour b茅n茅ficier potentiellement 脿 une population de patients plus large.
Oncolytics Biotech (NASDAQ: ONCY) hat die Genehmigung vom Paul-Ehrlich-Institut in Deutschland erhalten, um die Rekrutierung in Kohorte 5 der GOBLET-Studie fortzusetzen, die pelareorep in Kombination mit mFOLFIRINOX, mit oder ohne Atezolizumab, f眉r neu diagnostizierte Patienten mit duktalem Adenokarzinom des Pankreas bewertet.
Die Genehmigung folgt einer positiven Sicherheitsbewertung durch das unabh盲ngige Daten-Sicherheits眉berwachungsgremium und erm枚glicht die vollst盲ndige Rekrutierung von 30 Patienten in Phase 1. Erste Sicherheitsdaten werden auf dem ASCO Symposium f眉r gastrointestinalen Krebs 2025 pr盲sentiert, w盲hrend erste Wirksamkeitsergebnisse in der zweiten H盲lfte 2025 erwartet werden.
Das Unternehmen berichtet von ermutigenden Tumoransprechraten aus einer fr眉heren GOBLET-Kohorte, was auf das Potenzial von pelareorep hinweist, die Ergebnisse bei Patienten mit metastasiertem Bauchspeicheldr眉senkrebs zu verbessern. Die aktuelle Kohorte untersucht eine andere Chemotherapie-Kombination, um m枚glicherweise einer breiteren Patientengruppe zugutekommen zu k枚nnen.
- Regulatory approval received to continue patient enrollment in GOBLET study Cohort 5
- Positive safety review from independent Data Safety Monitoring Board
- Early encouraging tumor response rates from previous GOBLET cohort
- None.
Insights
The PEI's approval for GOBLET study's Cohort 5 continuation represents a important milestone in pelareorep's development pathway. The combination of pelareorep with mFOLFIRINOX, with or without atezolizumab, targets first-line PDAC treatment - a significant market opportunity given pancreatic cancer's poor prognosis and treatment options.
The DSMB's positive safety review is particularly noteworthy as mFOLFIRINOX is already known for its challenging side effect profile. The ability to combine pelareorep safely with this regimen suggests a manageable therapeutic window. The 30-patient enrollment target for Stage 1 is appropriately sized for an early efficacy signal while managing development costs.
In simpler terms: Think of this like testing if a new ingredient (pelareorep) can be safely added to an existing recipe (chemotherapy) to make it work better. The safety reviewers gave a thumbs up and now they can test it in more patients.
The strategic selection of mFOLFIRINOX as the combination partner is particularly astute. mFOLFIRINOX is already considered the most effective first-line chemotherapy for PDAC patients with good performance status. By demonstrating compatibility with this backbone therapy, Oncolytics positions pelareorep to potentially enhance outcomes in the optimal treatment setting.
Building on previous GOBLET cohort data showing encouraging response rates, this expansion provides a critical opportunity to validate pelareorep's efficacy with a different chemotherapy combination. The inclusion of an atezolizumab arm also allows exploration of potential synergy between viral and checkpoint immunotherapies - a mechanism of particular interest in typically "cold" tumors like PDAC.
For non-experts: Pancreatic cancer is one of the hardest cancers to treat. This study combines a new immunotherapy approach with the current best chemotherapy to try to improve patient survival. The early safety results are promising enough to expand the trial.
New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1
Following a positive safety review by the independent Data Safety Monitoring Board (DSMB), which recommended continuation, the PEI's approval allows Cohort 5 to progress to full enrollment. Early safety data will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium later this month, with initial efficacy results expected in the second half of the year.
"Pelareorep has the potential to meaningfully improve outcomes for patients with metastatic pancreatic cancer," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. "Encouraging tumor response rates observed in an earlier cohort of the GOBLET study underscore pelareorep's promise in this disease.听 GOBLET Cohort 5 extends our evaluation by testing pelareorep with a different chemotherapy regimen, mFOLFIRINOX, which broadens the range of pancreatic cancer patients who may benefit from this innovative therapy. Positive results from this cohort may ultimately enable pelareorep to benefit the large majority of metastatic pancreatic patients for whom improved treatment options are badly needed."
About GOBLET Cohort 5听
The mFOLFIRINOX cohort of the Phase 1/2 GOBLET study is designed to evaluate newly diagnosed metastatic PDAC patients treated with pelareorep + mFOLFIRINOX with or without atezolizumab. A three-patient safety run-in was incorporated to evaluate the safety and tolerability of each treatment arm: pelareorep + mFOLFIRINOX + atezolizumab and pelareorep + mFOLFIRINOX. A total of fifteen evaluable patients will be randomized to each arm in Stage 1 of this Simon two-stage study. The co-primary endpoints are objective response rate and safety.听If Stage 1 success criteria are met, one or both treatment arms may be expanded to Stage 2, in which 17 additional evaluable patients per arm will be enrolled. Blood and tumor samples will also be collected for translational evaluations.
About GOBLET听
The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in
- Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st听line advanced/metastatic PDAC patients;
- Pelareorep in combination with atezolizumab in 1st听line MSI (microsatellite instability)-high metastatic colorectal cancer patients;
- Pelareorep in combination with atezolizumab and TAS-102 in 3rd听line metastatic colorectal cancer patients;
- Pelareorep in combination with atezolizumab in 2nd听line or later advanced and unresectable anal cancer patients; and
- Pelareorep in combination with mFOLFIRINOX with and without atezolizumab in newly diagnosed metastatic PDAC patients.
Any cohort meeting pre-specified efficacy criteria in Stage 1 may be advanced to Stage 2 and enroll additional patients.
About AIO
AIO-Studien-gGmbH (AIO) emerged from the study center of the听听within the German Cancer Society (DKG). AIO operates with a non-profit purpose of promoting science and research with a focus on medical oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit:听听or follow the company on social media on 听and on X @.
Tecentriq庐 (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; continued enrollment in the GOBLET study and the expansion thereof to additional participants; our belief that pelareorep is poised to advance to registration-enabling studies for the treatment of breast and pancreatic cancers; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com
听
Logo - https://mma.prnewswire.com/media/1762876/Oncolytics_Biotech_New_Logo.jpg听
听
View original content:
SOURCE Oncolytics Biotech庐 Inc.
FAQ
What is the latest regulatory approval received by Oncolytics Biotech (ONCY) for their pancreatic cancer treatment?
How many patients will be enrolled in Stage 1 of ONCY's GOBLET study Cohort 5?
When will ONCY release the initial efficacy results for the GOBLET study Cohort 5?
What combination therapy is being tested in ONCY's GOBLET study Cohort 5?
When will ONCY present the early safety data from the GOBLET study Cohort 5?
